HEXO & Aphria: 2 Pot Stocks Under C$10

Summary

  • HEXO scrips are up nearly 60 per cent in the last one month, driven by the latest pot stock rally across North American markets.
  • Aphria stocks have yielded nearly 15 per cent returns in the last one month on the back of its merger with Tilray Inc.
  • Both pot stocks are placed among TMX’s top healthcare companies, guided by their stock performances.

 

It has been a remarkable second half of 2020 for the cannabis industry. Investors have been betting big on the pot stocks with hopes of the US legalizing marijuana at federal level. The entire cannabis industry is on the verge of massive expansion. The S&P/TSX Cannabis Index is up over 61 per cent quarter-to-date.

Let us take a look at two Canadian pot stocks that are also trading on the US exchanges:

 

HEXO Corp. (TSX: HEXO)

 

Stocks of the consumer-packaged cannabis firm have shot up over 44 per cent in the last three months. The scrips of the global marijuana supplier have swelled nearly 60 per cent in the last one month, guided by the latest pot stock rally across North American markets.

The small-cap company has over 122 million outstanding listed units on the Toronto Stock Exchange (TSX).

HEXO’s stocks made it to TMX’s Top Healthcare companies that have outperformed their peers with the highest price gains across the TSX and the TSX Venture (TSXV) in the last 30 days. Its 30-day stock trading volume stands at approximately 1.18 million units.

The cannabis stock’s current market cap is nearly C$ 670.6 million. Its present price-to-book (P/B) ratio stands at 1.215, as per the TMX portal data.

In the first quarter of fiscal 2021, the company registered a record gross revenue of C$ 41.3 million, a 14 per cent rise quarter-over-quarter (QoQ), and a 114 per cent surge year-over-year (YoY).

The cannabis manufacturer posted an adjusted EBITDA loss with an 87 per cent drop year-over-year to C$ 0.42 million in Q1 FY21.

Aphria Inc. (TSX: APHA)

 

The Ontario-based firm produces and sells medicinal and recreational marijuana. The company has recently confirmed its merger with Tilray Inc (NASDAQ: TLRY) to expand its footprints in the US market.

The midcap pot stock has surged by over 69 per cent in the last three months. Its units have delivered nearly 15 per cent returns in the last one month, led by its merger news. It has a current market cap of C$ 2.84 million.

Aphria also made it to TMX’s Top healthcare companies. Its 10-day average trading volume is nearly 3.77 million units. Consequently, the stock ranks among TMX’s top volume performers that have traded actively across the market in the last 10 days.

The stock has a P/B ratio of 1.523 and a present price-to-cashflow (P/CF) ratio of 2681.60. Its debt-to-equity (D/E) ratio stands at 0.23, according to TMX data.

In the first quarter of FY21, the company posted net cannabis revenue of C$ 62.5 million, a rise of 103 per cent YoY. The company posted an adjusted EBITDA of C$ 10.4 million from cannabis operations in the first quarter, a surge of 11 per cent quarter-over-quarter.

Comment


Disclaimer

   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK